Veyong Pharma attended at the 22nd CPHI China 2024

From June 19 to 21, the 22nd CPHI China and the 17th PMEC China were held at New International Expo Center in Shanghai . Li Jianjie, general manager of Veyong Pharma, a subsidiary of Limin Pharmaceuticals, Dr. Li Linhu, deputy director of the R&D Center of Limin Pharmaceuticals, Dr. Si Zhenjun, director of the Biological R&D Laboratory, Nie Fengqiu, director of the Synthetic R&D Laboratory, Li Jieqing, general manager of the International Marketing Center of Veyong Pharma, and Chen Lusheng, director of the Logistics Management Department, attended the exhibition with their international marketing team.

At booth E2A20, Veyong Pharma displayed ivermectin, abamectin, tiamulin fumarate, eprinomectin and other products to customers  around the world. The company’s leading products have passed the US FDA and EU CEP certifications and entered the international high-end market. Its perfect matrix layout, reliable product quality and rich product variety have been favored by many exhibitors.

The exhibition site was crowded with people. The international marketing team was in full swing, had in-depth exchanges with visitors who came to consult, listened carefully to customer needs, and gave professional answers, showing the comprehensive brand strength and cooperation value of Veyong to the global market, and established extensive connections with potential customers on site.

This exhibition has broadened Veyong Pharma’s sales channels in the international market and further consolidated the company’s reputation and influence in the international API market. In the future, the company will continue to accelerate the pace of international market development and further enhance Veyong Pharma’s brand influence and market competitiveness in the field of APIs and preparations.